Contezolid
Phase 3Small molecule
Contezolid is one of 90 small molecule programs targeting Abscess. It is currently in Phase 3.
3
Indications
6
Total Trials
6
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
297 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Sitafloxacin
Daiichi SankyoPhase 3
Contezolid
BBin Cao
Phase 3
Isoniazid and Rifapentine
CCenters for Disease Control and Prevention
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Tivicay
GSKPreclinical
Biktarvy
GileadPreclinical
Cabenuva
GSKPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tuberculosis2 trials
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled
Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis
Enrolling by invitation·—·Phase 1/2·NCT06811012·24 enrolled
Mycobacterium Avium Complex Pulmonary Disease1 trial
Meningitis1 trial
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Enrolling by invitation·—·Phase 1/2·NCT06811025·24 enrolled
Abscess1 trial
Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease
Enrolling by invitation·—·Phase 2·NCT07372781·24 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Contezolid. EMBL-EBI & Wellcome Sanger Institute.
- [4]